Furthermore, rapamycin, the mTOR inhibitor, abolished GABA-induced defects in yeast, and mammalian cells, as well as in murine models of heritable succinic semialdehyde dehydrogenase deficiency, which is an infrequent GABA metabolism defect. Here, MTOR is linked to succinic semialdehyde dehydrogenase deficiency.